Dr. David J. Young, MD PhD

Pediatric Hematologist and Oncologist @nih_nhlbi #SAA #IBMFS #DBA #RUNX1 #FPD #MDS Comments are mine

[Dr. David J. Young, MD PhD @DrDavidJYoung]

If you or someone you know or provide care for has RUNX1 Familial Platelet Disorder, please reach out to the @genome_gov RUNX1 Natural History Study. #HemeTwitter #RUNX1 #FPD

https://t.co/avvNnwmVgr

[Dr. David J. Young, MD PhD @DrDavidJYoung]

@bhavishap29 demonstrating how the @nih_nhlbi looks to treat all aspects of disease, including quality of life

[Emma M. Groarke @emmamgroarke]

Check out my @nih_nhlbi colleague @bhavishap29 ‘s poster reporting our work in patient reported outcomes in #VEXAS. Patients reported high symptom burden. #ASH24 @ASH_hematology

[Emma M. Groarke @emmamgroarke]

Congrats to @nih_nhlbi ‘s John Tisdale for winning the @ASH_hematology #ASH24 Beutler Prize! #SCD #ASHKudos

[Emma M. Groarke @emmamgroarke]

Congrats to @MedicineAtUL Denis O’Keeffe for presenting the result of the 🇮🇪ish collaborative TILLIRI study - looking at #VTE prophylaxis in lower limb injuries. @ASH_hematology #ASH24 @fniainle @oconnn04 @nontheistMike

[Dr. David J. Young, MD PhD @DrDavidJYoung]

Always proud to call these three colleagues and can’t wait to show the world what we’ve been working on as a team!

[Fernanda Gutierrez-Rodrigues @fergutierrezro1]

Congrats to @FernandoCatto for his @ASH_hematology achievement award! 🥇 He presented our work on immunodeficiency in the @nih_nhlbi cohort of #TBDs, mostly adults with TERT/TERC mutations. A great way to finish the conference! #ASH24 @emmamgroarke @cedunbar80

[Emma M. Groarke @emmamgroarke]

Congrats to @JMNolan89 (now at @pmcancercentre) on his #ASH24 abstract achievement award for his PhD research @tcddublin @TCDTMI! @adrianbracken @CancerInstIRE 🇮🇪🇨🇦@ASH_hematology #Lmsm #ASHKudos

[Dr. David J. Young, MD PhD @DrDavidJYoung]

Farewell #ASH24. It has been a real pleasure, a great source of information, and an amazing opportunity for collaborations.

I’ve enjoyed sharing my experiences, and I only regret I could not share even more of the amazing hematology with everyone.

[Dr. David J. Young, MD PhD @DrDavidJYoung]

@RUNX1Research Enrollment in our study is absolutely free. For those who can join us in Bethesda at the @NIHClinicalCntr we are able to provide transportation and lodging. And we cover the costs of all testing (which is only to your level of comfort and desired involvement) #RUNX1

[Dr. David J. Young, MD PhD @DrDavidJYoung]

If you or someone you know or provide care for has RUNX1 Familial Platelet Disorder, please reach out to the @genome_gov RUNX1 Natural History Study. #HemeTwitter #RUNX1 #FPD

https://t.co/avvNnwmVgr

[Dr. David J. Young, MD PhD @DrDavidJYoung]

We also encourage all of our study participants and their families to connect with @RUNX1Research where they will find an amazing community of caring providers, researchers, and most importantly other people also on their RUNX1 Journeys. #RUNX1 #HemeTwitter #Platelets

[Dr. David J. Young, MD PhD @DrDavidJYoung]

https://t.co/eX2gLsdKoA

[Dr. David J. Young, MD PhD @DrDavidJYoung]

For those with lifelong bleeding, bruising, and/or low platelets but no diagnosis, the @genome_gov RUNX1 Program can offer focused testing for those without the resources to get more comprehensive testing elsewhere at no cost. Enrollment in our study is also free of cost.

[Dr. David J. Young, MD PhD @DrDavidJYoung]

Diversity in research is essential for research equity and equipoise. This is important for treatment AND natural history studies. At @genome_gov #RUNX1 Natural History Study we strive to learn about ALL people with FPDMM.

#ASH24 #HemeTwitter @ASH_hematology

[Dr. David J. Young, MD PhD @DrDavidJYoung]

This not only deprives these patients of the best care and prevention, but blinds us to the full extent of RUNX1 biology.

[Dr. David J. Young, MD PhD @DrDavidJYoung]

For those with lifelong bleeding, bruising, and/or low platelets but no diagnosis, the @genome_gov RUNX1 Program can offer focused testing for those without the resources to get more comprehensive testing elsewhere at no cost. Enrollment in our study is also free of cost.

[Dr. David J. Young, MD PhD @DrDavidJYoung]

https://t.co/Gxoe3EZnFF

[Dr. David J. Young, MD PhD @DrDavidJYoung]

If you or someone you know or provide care for has RUNX1 Familial Platelet Disorder, please reach out to the @genome_gov RUNX1 Natural History Study. #HemeTwitter #RUNX1 #FPD

https://t.co/avvNnwmVgr

[Dr. David J. Young, MD PhD @DrDavidJYoung]

At an #ASH24 that saw the wonderful blinatumomab results, it is frightening that pediatric AIHA can have mortality rates approaching 10%. We need better diagnostics, understanding and treatments.

[Dr. David J. Young, MD PhD @DrDavidJYoung]

Dr. Rachael Grace of @DFBC_PedCare presents a comprehensive analysis of pedi AIHA. Half of patients will have one episode. For the it is a recurrent condition. With 70% untested, there is a need for more universal genetics to help stratify risks/treatment. #ASH24 #HemeTwitter

[Dr. David J. Young, MD PhD @DrDavidJYoung]

How rare is “rare”?

@mmanupe presents uRADAR data demonstrating that with transnational efforts we can better identify, study, and even treat vanishingly uncommon disorders, which may actually be more prevalent than we think #ASH24 #HemeTwitter @ERNEuroBloodNet

[Dr. David J. Young, MD PhD @DrDavidJYoung]

Importantly, side effects and reactions were as good as, if not better than, iron sucrose

[Dr. David J. Young, MD PhD @DrDavidJYoung]

Iron deficiency is a critical issue during pregnancy. Oral repletion is inefficient with side effects. Traditional IV is intensive. Mary Morgan (@Sunnybrook @uoftmedicine) provides compelling data for ferric derisomaltose total dose infusion to treat pregnancy related #IDA #ASH24